Search

everythinglearnresearchcommunity

for

Search:↓

Certain ESR1 gene variations may affect hormone levels and fat distribution in women with high male hormone levels.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Oral contraceptives help mild hirsutism, while flutamide and spironolactone help severe cases.

The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

Researchers developed new compounds that target the androgen receptor effectively with fewer side effects.

Goserelin and oestradiol treatment slightly improved hairiness but did not significantly change sebum production or hair characteristics in mildly hirsute women.

High doses of norethindrone acetate in rats caused various organ changes but didn't significantly increase tumor rates.

Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.

Finasteride doesn't affect ovulation in normal women.

Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.

Ecklonia cava improves the effectiveness of Diane-35 in managing PCOS symptoms.

Finasteride may help some women with hair loss, but better options exist.

The combination treatment didn't work better than minoxidil alone and caused more menstrual issues.

Low-dose oral minoxidil and spironolactone combo effectively reduces hair loss and improves hair density in women.

Both Diane 35 combinations effectively and safely reduce hirsutism and acne, with potential for better results if treatment extends beyond 12 months.

Systemic cyproterone acetate and 5% topical minoxidil are effective and safe for treating female pattern hair loss.

New compounds called benzoquinolinones may treat conditions linked to excess DHT.

Selective androgen receptor modulators (SARMs) are a promising type of drug for various health conditions due to their targeted actions.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.

Low testosterone and 5α-reductase inhibitors can harm men's metabolic and sexual health; testosterone therapy may help, but discussing 5α-RIs' side effects is important.

Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.

Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.

Oral minoxidil may help with female hair loss.